Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved†‡
Potential conflict of interest: Nothing to report.
This correspondence first published online ahead of print on 27 Jun 2011, and has since been updated for print. The title has been revised.
This work was performed under the auspices of the U.S. Department of Energy under contract DE-AC52-06NA25396, and supported by National Institutes of Health grants RR06555-19, P20-RR018754-6, AI065256-5, R56-AI078881-01, and AI28433-20, the National Science Foundation under grant NSF PHY05-51164, and by the University of Illinois Walter Payton Liver Center GUILD.
No abstract is available for this article.